$ESPR
Esperion Therapeutics Inc

2020 Q2 Form 10-Q Financial Statement

#000110465920092840 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $212.2M $982.0K
YoY Change 21512.63%
Cost Of Revenue $400.0K
YoY Change
Gross Profit $211.8M
YoY Change
Gross Profit Margin 99.79%
Selling, General & Admin $47.68M $13.49M
YoY Change 253.4% 92.74%
% of Gross Profit 22.51%
Research & Development $34.99M $42.79M
YoY Change -18.23% 8.26%
% of Gross Profit 16.52%
Depreciation & Amortization $110.0K $60.00K
YoY Change 83.33% 0.0%
% of Gross Profit 0.05%
Operating Expenses $83.07M $56.28M
YoY Change 47.59% 21.08%
Operating Profit $129.2M -$55.30M
YoY Change -333.59% 18.97%
Interest Expense $4.640M $0.00
YoY Change -100.0%
% of Operating Profit 3.59%
Other Income/Expense, Net $81.00K $1.077M
YoY Change -92.48% 43.6%
Pretax Income $124.6M -$54.20M
YoY Change -329.89% 18.6%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $124.6M -$54.22M
YoY Change -329.82% 18.57%
Net Earnings / Revenue 58.71% -5521.49%
Basic Earnings Per Share $4.50 -$2.01
Diluted Earnings Per Share $4.32 -$2.01
COMMON SHARES
Basic Shares Outstanding 27.67M shares 26.97M shares
Diluted Shares Outstanding 28.85M shares 26.97M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $300.7M $301.2M
YoY Change -0.16% 67.16%
Cash & Equivalents $298.5M $274.3M
Short-Term Investments $2.247M $26.88M
Other Short-Term Assets $12.40M $5.900M
YoY Change 110.17% -32.18%
Inventory $8.248M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $321.4M $307.1M
YoY Change 4.64% 62.58%
LONG-TERM ASSETS
Property, Plant & Equipment $1.512M $903.0K
YoY Change 67.44% 201.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $1.294M
YoY Change
Total Long-Term Assets $8.981M $1.693M
YoY Change 430.48% -92.3%
TOTAL ASSETS
Total Short-Term Assets $321.4M $307.1M
Total Long-Term Assets $8.981M $1.693M
Total Assets $330.4M $308.8M
YoY Change 6.97% 46.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $29.69M $28.40M
YoY Change 4.53% 26.24%
Accrued Expenses $43.80M $22.30M
YoY Change 96.41% 81.3%
Deferred Revenue $1.134M $3.599M
YoY Change -68.49%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $83.88M $54.31M
YoY Change 54.44% 55.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $161.0M $125.2M
YoY Change 28.59%
Total Long-Term Liabilities $161.0M $125.2M
YoY Change 28.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $83.88M $54.31M
Total Long-Term Liabilities $161.0M $125.2M
Total Liabilities $244.9M $179.5M
YoY Change 36.43% 412.8%
SHAREHOLDERS EQUITY
Retained Earnings -$648.9M -$564.9M
YoY Change 14.86%
Common Stock $28.00K $27.00K
YoY Change 3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.49M $129.3M
YoY Change
Total Liabilities & Shareholders Equity $330.4M $308.8M
YoY Change 6.97% 46.43%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $124.6M -$54.22M
YoY Change -329.82% 18.57%
Depreciation, Depletion And Amortization $110.0K $60.00K
YoY Change 83.33% 0.0%
Cash From Operating Activities $139.4M -$54.01M
YoY Change -358.08% 37.78%
INVESTING ACTIVITIES
Capital Expenditures -$590.0K -$230.0K
YoY Change 156.52%
Acquisitions
YoY Change
Other Investing Activities $5.700M $26.95M
YoY Change -78.85% -14.63%
Cash From Investing Activities $5.110M $26.71M
YoY Change -80.87% -15.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.680M 126.5M
YoY Change -97.09% 10533.61%
NET CHANGE
Cash From Operating Activities 139.4M -54.01M
Cash From Investing Activities 5.110M 26.71M
Cash From Financing Activities 3.680M 126.5M
Net Change In Cash 148.2M 99.24M
YoY Change 49.31% -1640.99%
FREE CASH FLOW
Cash From Operating Activities $139.4M -$54.01M
Capital Expenditures -$590.0K -$230.0K
Free Cash Flow $140.0M -$53.78M
YoY Change -360.28% 37.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27497911
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27751655
dei Entity Central Index Key
EntityCentralIndexKey
0001434868
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2019Q4 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
11871000
CY2020Q2 espr Revenue Interest Liability Current
RevenueInterestLiabilityCurrent
9276000
CY2019Q4 espr Revenue Interest Liability Current
RevenueInterestLiabilityCurrent
5236000
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1134000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2152000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2232000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
454000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
83881000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
66080000
CY2020Q2 espr Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
157015000
CY2019Q4 espr Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
127308000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3967000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1109000
CY2020Q2 us-gaap Liabilities
Liabilities
244863000
CY2019Q4 us-gaap Liabilities
Liabilities
194497000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27751655
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27497911
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
28000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
734365000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-648904000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-695266000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
85489000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
19950000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
330352000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
214447000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
212236000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
982000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
214076000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146401000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35986
dei Entity Registrant Name
EntityRegistrantName
Esperion Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1870780
dei Entity Address Address Line1
EntityAddressAddressLine1
3891 Ranchero Drive, Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
Ann Arbor
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48108
dei City Area Code
CityAreaCode
734
dei Local Phone Number
LocalPhoneNumber
887-3903
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ESPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27825428
CY2020Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
398000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298489000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166130000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
928000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2247000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
34651000
CY2020Q2 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
890000
CY2019Q4 espr Prepaid Clinical Development Costs Current
PrepaidClinicalDevelopmentCostsCurrent
6081000
CY2020Q2 us-gaap Inventory Net
InventoryNet
8248000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11497000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3924000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
321371000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
211714000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1512000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1145000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6175000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1532000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1294000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56000
CY2020Q2 us-gaap Assets
Assets
330352000
CY2019Q4 us-gaap Assets
Assets
214447000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
29690000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
28856000
CY2020Q2 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
19641000
CY2019Q4 espr Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
17511000
CY2020Q2 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
21908000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
429000
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
34987000
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
42788000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
69689000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
89096000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47681000
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13492000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
715166000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
23000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
89234000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25674000
us-gaap Net Income Loss
NetIncomeLoss
33158000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-55298000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
83066000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
56280000
us-gaap Operating Expenses
OperatingExpenses
159352000
us-gaap Operating Expenses
OperatingExpenses
114770000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
129170000
us-gaap Operating Income Loss
OperatingIncomeLoss
54724000
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.50
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.68
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-54221000
us-gaap Net Income Loss
NetIncomeLoss
46362000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
124611000
us-gaap Operating Income Loss
OperatingIncomeLoss
31631000
CY2020Q2 us-gaap Interest Expense
InterestExpense
4640000
us-gaap Interest Expense
InterestExpense
8811000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
81000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1077000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
449000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1527000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.23
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.32
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.16
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27665728
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26968818
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27592479
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26906149
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28854445
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26968818
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28948058
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28518015
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-9000
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
95000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-23000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
303000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
124602000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54126000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46339000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
33461000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
79118000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1669000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6636000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
208000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
87379000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
175010000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1887000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6563000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
95000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-54221000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
129334000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
19950000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1014000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7053000
us-gaap Depreciation
Depreciation
224000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-78249000
us-gaap Depreciation
Depreciation
126000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-50246000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3738000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7395000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2382000
us-gaap Share Based Compensation
ShareBasedCompensation
14448000
us-gaap Share Based Compensation
ShareBasedCompensation
13199000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
124611000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
85489000
us-gaap Profit Loss
ProfitLoss
46362000
us-gaap Profit Loss
ProfitLoss
33158000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
93000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
121000
espr Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
8811000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1840000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1018000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3599000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8248000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1238000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
921000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-16705000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
12257000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2586000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
70044000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
37682000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4420000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
36895000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
72835000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
776000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
423000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31699000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
72412000
espr Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
25000000
espr Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs
ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
124649000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4752000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3556000
espr Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
64000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29688000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
128205000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
131431000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
238299000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167058000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36973000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298489000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
275272000
espr Issuance Costs From Royalty Interest Purchase Agreement Not Yet Paid
IssuanceCostsFromRoyaltyInterestPurchaseAgreementNotYetPaid
240000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
285000
espr Non Cash Right Of Use Asset
NonCashRightOfUseAsset
-7000
espr Non Cash Right Of Use Asset
NonCashRightOfUseAsset
26000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Concentration of Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of June 30, 2020, one customer accounted for all of the Company's net trade receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4961000
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2869000
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
418000
CY2020Q2 us-gaap Inventory Net
InventoryNet
8248000
CY2020Q2 espr Investments And Cash Amortized Cost
InvestmentsAndCashAmortizedCost
289879000
CY2020Q2 espr Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
289879000
CY2019Q4 espr Investments And Cash Amortized Cost
InvestmentsAndCashAmortizedCost
62589000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
23000
CY2019Q4 espr Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
62612000
CY2020Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
0
CY2019Q4 espr Revenue Interest Liability
RevenueInterestLiability
132544000
espr Revenue Interest Liability Decrease For Payments Made
RevenueInterestLiabilityDecreaseForPaymentsMade
64000
CY2020Q2 espr Revenue Interest Liability
RevenueInterestLiability
166291000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10868000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7818000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5864000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3842000
CY2020Q2 espr Accrued Inventory Current
AccruedInventoryCurrent
1771000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3405000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
211000
CY2020Q2 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
21908000
CY2019Q4 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
11871000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4677929
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
39.31
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M25D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
109054000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
234940
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
61.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
134945
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
56.38
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
200157
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
23.74
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4577767
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
72396000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4577767
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
40.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
72396000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3195452
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
35.88
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M13D
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
65786000
espr Operating Lease Increase Decrease In Right Of Use Assets
OperatingLeaseIncreaseDecreaseInRightOfUseAssets
4600000
espr Operating Lease Increase Decrease In Operating Lease Liabilities
OperatingLeaseIncreaseDecreaseInOperatingLeaseLiabilities
4600000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
600000
us-gaap Operating Lease Cost
OperatingLeaseCost
800000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.036
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1209000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2380000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2333000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
584000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6506000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
307000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6199000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
124611000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-54221000
us-gaap Net Income Loss
NetIncomeLoss
46362000
us-gaap Net Income Loss
NetIncomeLoss
33158000
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27665728
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26968818
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27592479
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26906149
CY2020Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1188717
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1355579
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1611866
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28854445
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26968818
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28948058
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28518015
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.50
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.23
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.32
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.16
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2722497
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5406464
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2581939
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2589345
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298489000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
274344000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166130000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36973000
CY2019Q2 us-gaap Restricted Cash
RestrictedCash
928000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
928000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298489000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
275272000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167058000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36973000

Files In Submission

Name View Source Status
0001104659-20-092840-index-headers.html Edgar Link pending
0001104659-20-092840-index.html Edgar Link pending
0001104659-20-092840.txt Edgar Link pending
0001104659-20-092840-xbrl.zip Edgar Link pending
espr-20200630.xsd Edgar Link pending
espr-20200630x10q.htm Edgar Link pending
espr-20200630x10q_htm.xml Edgar Link completed
espr-20200630xex10d1.htm Edgar Link pending
espr-20200630xex10d1003.jpg Edgar Link pending
espr-20200630xex10d1004.jpg Edgar Link pending
espr-20200630xex10d2.htm Edgar Link pending
espr-20200630xex10d3.htm Edgar Link pending
espr-20200630xex31d1.htm Edgar Link pending
espr-20200630xex31d2.htm Edgar Link pending
espr-20200630xex32d1.htm Edgar Link pending
espr-20200630_cal.xml Edgar Link unprocessable
espr-20200630_def.xml Edgar Link unprocessable
espr-20200630_lab.xml Edgar Link unprocessable
espr-20200630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending